ATV-1601 Treatment for Hereditary Hemorrhagic Telangiectasia
Part of Blood & lymphatic, Genetic & congenital, Heart & circulation clinical trials.
This trial tests a new drug called ATV-1601 in people with HHT, a genetic condition that causes abnormal bleeding and blood vessel problems. The drug aims to reduce bleeding and anemia caused by HHT.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of HHT (hereditary hemorrhagic telangiectasia), a genetic bleeding disorder
- Your HHT is moderate to severe with a specific symptom score of 4 or higher
- You have anemia or needed at least one blood transfusion in the past 6 months
- Your blood, kidney, and liver function tests are adequate for the study
- You are not pregnant, not breastfeeding, and able to use effective birth control during and after the study
- You have not taken an AKT inhibitor before (a type of cancer drug)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug, TX002100, for people with hereditary hemorrhagic telangiectasia (HHT) who need regular intravenous iron infusions or blood transfusions to manage bleeding. The goal is to see if it reduces the need for these supportive treatments.
This trial tests a new topical gel (TOR-582) applied inside the nose to reduce nosebleeds in people with HHT. It may help by targeting the abnormal blood vessels that cause frequent bleeding.
This study looks at how well the drug Bevacizumab works and how safe it is for people with HHT who have severe liver problems that cause their heart to pump too much blood. It aims to help doctors understand if this treatment can help manage these serious symptoms.
This study tests a new medicine called ADX-324 to see if it can prevent HAE attacks in adults with type I or II HAE. If you've had attacks recently and are willing to pause your current prevention medication, this trial may be an option.
This study tests a new drug called DIAG723 in adults with hereditary hemorrhagic telangiectasia (HHT), a genetic condition that causes abnormal blood vessels and bleeding. Depending on which part of the study you qualify for, the drug may help reduce nosebleeds, improve anemia, or help with lung blood vessel problems caused by HHT.
This trial tests whether nintedanib can reduce how often and how severe nosebleeds are in adults with hereditary hemorrhagic telangiectasia (HHT). It may help by calming blood-vessel problems that cause bleeding.
Hear when a new Hereditary Hemorrhagic Telangiectasia (HHT) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.